source
- Xenon shares tumble up to 30% after pausing depression trial over neuropsychiatric eventsXenon Pharmaceuticals announced it is pausing enrollment in its depression trial for the drug azetukalner after neuropsychiatric adverse events emerged that were not observed in earlier testing. A…
- Electra Therapeutics raises $350 million in Nasdaq IPO to fund commercial expansionElectra Therapeutics announced that it priced its initial public offering on the Nasdaq at $350 million, becoming the 21st biotech to go public in 2026. The Bay Area‑based company said the capital…